levels were below usual therapeutic ranges (MER: 2–8 mg/L, PIP 8–30 mg/L). This was more often the case in presence of concomitant HF (MER: 92%, PIP: 83%), often associated with neutropenia. Low exposure was observed not only at initial intensive dosage (MER: 120 mg/kg/day, PIP: 400 mg/kg/day) but tended to persist despite dosage readjustment based on concentration monitoring. Moreover, bacteremia was diagnosed in 38 cases.

Conclusion Current recommended doses of MER and PIP do not provide optimal concentration coverage throughout the dosing interval in a large fraction of children with cancer and febrile neutropenia as a result of HF. Monitoring of beta-lactams should be offered to all cancer children to ensure best therapeutic success and avoid the development of resistance.

REFERENCES

Disclosure(s) Nothing to disclose

013 IMPROVED EARLY VANCOMYCIN EXPOSURE IN NEONATES USING A POPULATION PHARMACOKINETIC MODEL-BASED VANCOMYCIN DOSING REGIMEN

A Smits**, 3E De Saeger, 4A Vandendriessche, 1,2VC o s s e y, 5,6K Allegaert. 1Neonatal Intensive Care Unit, University Hospitals Leuven; 2Department of Development of Regeneration; 3Faculty of Medicine, KU Leuven, Leuven; 4Department of Pediatrics, Imelda Hospital, Bonheiden; 5Department of Development of Regeneration, KU Leuven, Leuven, Belgium; 6Neonatology, Intensive Care and Department of Surgery, Erasmus MC Sophia Children’s Hospital, Rotterdam, The Netherlands

Background We previously documented that 2 published vancomycin dosing regimens resulted in subtherapeutic exposure in 66.3 and 76.2% of neonates. A new dosing regimen derived from a population pharmacokinetic (PK) analysis and using a loading dose, was implemented in our unit. We aimed to investigate if the new regimen results in improved vancomycin exposure (target trough 10–15 mg/L).

Methods Clinical data and early (24 h after start) vancomycin therapeutic drug monitoring (TDM) in neonates receiving vancomycin for medical reasons, were retrospectively collected and pooled with 2 historical cohorts (cohort 1 (2011, n=193 observations), dosing based on birthweight, PNA and pooled with 2 historical cohorts (cohort 1 (2011, n=193 observations), dosing based on birthweight, PNA and postnatal age (PNA)]. The new regimen [cohort 3 (2018, n=71 observations)] consists of a loading dose, followed by dosing based on birthweight, PNA and ibuprofen co-treatment. Clinical characteristics and early TDM were compared across the cohorts using the Kruskal-Wallis Test. Results were significant if p< 0.05.

Results Clinical characteristics (cohort 1, 2 and 3 respectively) did not differ significantly across the cohorts. Median (IQ range) GA was 32.8 (28.4–37.6), 32.1 (28.5–37.5), 28 (26–38) weeks with p=0.097; PNA 13 (6–26), 12 (7–23), 14 (10–25) days with p=0.15 and creatininemia 0.43 (0.33–0.55), 0.49 (0.33–0.65), 0.45 (0.32–0.57) mg/dL with p=0.15. Median vancomycin trough level was 7.8 (5.1–11.3), 5.8 (4.1–8.7), 13.3 (9.9–17.3) mg/L with p< 0.0001. With the new regimen, 25.4% of trough levels was < 10 mg/L, 40.8% >15 mg/L, and 33.8% was on target, versus 23.3 and 19.8% on target in cohort 1 and 2 respectively.

Conclusion A population PK model-based vancomycin dosing regimen using a loading dose, resulted in improved neonatal vancomycin exposure. Although only 25% of trough levels was subtherapeutic, dosing optimisation for cases with supratherapeutic exposure is also needed, as well as further prospective validation.

REFERENCES

Disclosure(s) Nothing to disclose

014 PATERNAL ACITRETIN EXPOSURE AND PREGNANCY RISKS

M Nørgaard**, 1JT Andersen. 1Department of Clinical Pharmacology, Copenhagen University Hospital Bispebjerg and Frederiksberg Hospital, Copenhagen NV; 2University of Copenhagen, Faculty of Health and Medical Sciences, Copenhagen, Denmark

Background In the literature it is well known that acitretin is highly teratogenic when used in pregnant women. Therefore, several restrictions to all fertile women prior, during and up to three years after ended treatment are recommended. However, as for paternal acitretin exposure data is very limited leading to worries and anxiety among couples planning or already pregnant.

Methods We conducted a nationwide cohort study during the period between 1996–2016 investigating paternal acitretin exposure and the risk of spontaneous abortions and the association to major malformation. Data were obtained from the Medical Birth Registry and the National Hospital Registry. All fathers exposed to acitretin were identified by the Danish National Prescription Registry.

Results We identified in total 1.477.252 registered pregnancies with known father identity. Of these 244 pregnancies and 205 children were exposed to paternal acitretin treatment between one year prior to conception to the end of first trimester. The adjusted hazard risk (HR) of spontaneous abortion was 0.71 (95% CI: 0.43–1.17). When analysing exposure three months prior to conception and during first trimester only, the adjusted HR was 0.76 (95% CI:0.38–1.51) and 1.06 (95% CI:0.55–2.04), respectively. As for the association between major malformation and paternal acitretin exposure between one year prior to conception to the end of first trimester the adjusted odds ratio (OR) was 1.15 (95% CI: 0.57–2.34). When stratifying for the period of acitretin exposure the same insignificant trend was detected. In addition, both spontaneous abortions and major malformation were independent of dosage.

Conclusion We found no increased risk of spontaneous abortions or major malformation in pregnancies exposed to paternal acitretin one year before to three months after conception. This was persistent when sub-analysing exposure period and dosage. These data are an important contribute to the sparse evidence suggesting that paternal acitretin exposure during fertility is safe.

Disclosure(s) Nothing to disclose